+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Actively Recruiting

Phase 4
Age: 18Years +
FEMALE
ID05465031

Preventing Heart Damage in Women With Breast Cancer Using SacubitrilValsartan During Chemotherapy

Led by Silesian Centre for Heart Diseases · Updated on 2025-03-14

600

Participants Needed

4

Research Sites

61 weeks

Total Duration

AI-Summary

What This Trial Is About

Breast cancer is the most common cancer among women worldwide, with over 2.25 million new cases reported in 2020. While modern treatments like surgery, radiotherapy, hormone therapy, and targeted chemotherapy have improved survival, they often lead to cardiotoxicity, which can cause heart failure or reduced heart function. This trial evaluates whether sacubitrilvalsartan, a drug used for heart failure, can prevent cardiotoxicity in breast cancer patients receiving chemotherapy, particularly with anthracyclines or HER-2 targeted therapies. The study is a randomized, double-blind, placebo-controlled trial involving 480 women with confirmed breast cancer eligible for chemotherapy with anthracyclines andor HER-2 monoclonal antibodies. Participants first undergo a single-blind phase to test drug tolerance, then are randomly assigned to receive either sacubitrilvalsartan or placebo for up to 24 months. The sacubitrilvalsartan dose starts at 100 mg twice daily, increasing to a target dose of 200 mg twice daily if tolerated. Study drug doses may be adjusted based on patient tolerance. Standard breast cancer treatments continue alongside the study intervention. Participants will have multiple study visits at 3, 12, and 24 months post-randomization. These visits include heart function assessments with echocardiography, optional MRI scans, electrocardiograms including 24-hour Holter monitoring, blood tests including cardiac biomarkers, functional capacity tests, and quality of life questionnaires. The main outcome is the change in left ventricular ejection fraction over 24 months. Safety and other heart-related events will also be monitored. Genetic testing may be performed to explore individual responses to the drug. The study lasts up to 24 months with ongoing follow-up and monitoring.

CONDITIONS

Brief Title

Sacubitril/Valsartan in PriMAry preventIoN of the Cardiotoxicity of Systematic breaST canceR trEAtMent (MAINSTREAM)

Research Team

M

Mateusz Tajstra, MD, PhD, Assoc Prof

L

Lucyna Broja

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here